Effect of fluvoxamine and erythromycin on the pharmacokinetics of oral lidocaine

Basic and Clinical Pharmacology and Toxicology

Volumn 99, Issue 2, 2006, Pages 168-172

  Isohanni, Mika H ^a,b   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^c  

^a Diacor Hospital   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYLIDOCAINE; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; DEETHYLLIDOCAINE; ERYTHROMYCIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETIDOCAINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; ITRACONAZOLE; LIDOCAINE; PLACEBO; ROXITHROMYCIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; FIRST PASS EFFECT; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ANESTHETICS, LOCAL; AREA UNDER CURVE; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; ERYTHROMYCIN; FEMALE; FLUVOXAMINE; HALF-LIFE; HUMANS; LIDOCAINE; MALE; METABOLIC CLEARANCE RATE; NAUSEA;

EID: 33747068772     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_482.x     Document Type: Article

References (25)

1. Bargetzi, M. J., T. Aoyama, F. J. Gonzales & U. A. Meyer: Lignocaine metabolism in human liver microsomes by P450IIIA4. Clin. Pharmacol. Therap. 1989, 46, 521-527.
2. Benowitz, N. L. & W. Meister: Clinical pharmacokinetics of lignocaine. Clin. Pharmacokinet. 1978, 3, 177-201.
3. Brøsen, K., E. Skjelbo, B. B. Rasmussen, H. E. Poulsen & S. Loft: Fluvoxamine is a potent inhibitor of cytochrome P4501A. Biochem. Pharmacol. 1993, 45, 1211-1214.
4. Burney, R. G., C. A. Difazio, M. J. Peach, K. A. Petrie & M. J. Silvester: Antiarrhythmic effects of lidocaine metabolites. Amer. Heart J. 1974, 88, 765-769.
5. Dawling, S., R. J. Flanagan & B. Widdop: Fatal lignocaine poisoning: report of two cases and review of the literature. Hum. Toxicol. 1989, 8, 389-392.
6. Demedts, P., A. Wauters, F. Franck & H. Neels: Simultaneous determination of lidocaine, bupivacaine and their two main metabolites using gas chromatography and a nitrogen-phosporus detector: Selection of stationary phase and chromatographic conditions. Ther. Drug Monit. 1996, 18, 208-211.
7. Fuhr U., E. M. Anders, G. Mahr, F. Sorgel & A. H. Staib: Inhibitory potency of quinolone antibacterial agents against cytochrome P4501A2 activity in vivo and vitro. Antimicrob. Agents Chemoter. 1992, 36, 942-948.
8. Gonzalez del Rey, J., S. Wason & R. W. Druckenbrod: Lidocaine overdose: another preventable case? Pediatr. Emerg. Care 1994, 10, 344-346.
9. Hess, G. P. & P. D. Walson: Seizures secondary to oral viscous lidocaine. Ann. Emerg. Med. 1988, 17, 725-727.
10. Isohanni, M. H., P. J. Neuvonen & K. T. Olkkola: Effect of erythromycin and itraconazole on the pharmacokinetics of oral lignocaine. Pharmacology & Toxicology 1999, 84, 143-146.
11. Isohanni, M. H., P. J. Neuvonen, V. J. Palkama & K. T. Olkkola: Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine. Eur. J. Clin. Pharmacol. 1998, 54, 561-565.
12. Kivistö, K. T., G. Bookjans, M. F. Fromm, E. U. Griese, P. Munzel & H. K. Kroemer: Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue. Brit. J. Clin. Pharmacol. 1996, 42, 387-389.
13. Laakso, S., M. Scheinin & M. Anttila: Determination of erythromycin base and 2-acetylerythromycin in human plasma using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 1990, 526, 474-486.
14. Lorec, A.-M., B. Bruguerolle, L. Attolini & X. Roucoules: Rapid simultaneous determination of lidocaine, bupivacaine and their two main metabolites using capillary gas-liquid chromatography with nitrogen-phosporus detector. Ther. Drug Monit. 1994, 16, 592-595.
15. Martindale The Complete Drug Reference. Ed.: S. C. Sweetman. Pharmaceutical Press, London, UK, 2005, p. 1379.
16. Olkkola, K. T., M. H. Isohanni, K. Hamunen & P. J. Neuvonen: The effect of erythromycin and fluvoxamine on the pharmacokinetics of intravenous lidocaine. Anesth. Analg. 2005, 100,1352-1356.
17. Orlando, R., P. Piccoli, S. De Martin, R. Padrini & P. Palatini: Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. Brit. J. Clin. Pharmacol. 2003, 55, 86-93.
18. Orlando, R., P. Piccoli, S. De Martin, R. Padrini, M. Floreani & P. Palatini: Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: Effects of liver function. Clin. Pharmacol. Ther. 2004, 75, 80-88.
19. Rasmussen, B. B., J. Mäenpää, O. Pelkonen, S. Loft, H. E. Poulsen, J. Lykkesfeldt & K. Brøsen: Selective serotonin reuptake inhibitors and theophylline metabolism in human liver microsomes: potent inhibition by fluvoxamine. Brit. J. Clin. Pharmacol. 1995, 39, 151-159.
20. Shimada, T., H. Yamazaki, M. Mimura, Y. Inui & F. P. Guengerich: Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Therap. 1994, 270, 414-423.
21. Tucker, G. T. & L. E. Mather: Clinical pharmacokinetics of local anaesthetics. Clin. Pharmacokinet. 1979, 4, 241-278.
22. Van der Meersch-Mougeot, V. & B. Diquet: Sensitive one-step extraction procedure for column liquid chromatographic determination of fluvoxamine in human and rat plasma. J. Chromatogr. 1991, 567, 441-449.
23. Wang, J.-S., J. T. Backman, P. Taavitsainen, P. J. Neuvonen & K. T. Kivistö: Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans. Drug Metab. Dispos. 2000, 28, 959-965.
24. Wang, J.-S., J. T. Backman, X. Wen, P. Taavitsainen, P. J. Neuvonen & K. T. Kivistö: Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro. Pharmacology & Toxicology 1999, 85, 201-205.
25. Zuberi, B. F., M. R. Shaikh, N. U. Jatoi & W. M. Shaikh: Lidocaine toxicity in a student undergoing upper gastrointestinal endoscopy. Gut 2000, 46, 435.